Over the last fifteen years, Recordati has developed, produced and marketed medicines for the treatment of rare diseases through Recordati Rare Diseases, dedicated entirely to serving patients globally living with rare conditions and focused on key treatment areas including rare metabolic, endocrine and oncology.
To reflect its commitment in pediatric oncology, Recordati decided that the 11th edition of the International Prize for Scientific Research Arrigo Recordati will be dedicated to the promotion and recognition of excellence in research on pediatric oncology, specifically neuroblastoma.
Young investigators of all nationalities working in this area are eligible. Applicants should be independent junior faculty who are not more than ten years from their terminal degree or eight years from the end of their fellowship and who are not employed full-time with a pharmaceutical company.
Basic, translational, preclinical, and clinical research projects focusing on neuroblastoma are eligible.
The winning project will receive a € 100,000 research grant.
No institutional indirect costs (e.g., overhead costs) will be added or subtracted to\from the grant. However, if there is a requirement for an indirect cost payable to the institution, a special request must be made to Recordati S.p.A. explaining the special circumstances.
If approved, the maximum indirect rate would be 10% of the Prize. An annual progress report of the research project is expected.
Recordati recognises the value of basic research to elucidate the pathophysiology and the etiology of pediatric neuroblastoma, translational research to develop new diagnostic and therapies for early intervention, and clinical research to develop novel therapeutic strategies. Such research projects are sought for this competition.
Proposals should be based on strong preliminary results which support the project rationale.
If a proposed experimental treatment is based on a pre-existing treatment, the project is eligible only if the treatment is being repurposed from another indication or if its formulation, or administration is changed in a major way, in order to improve treatment quality, compliance, efficacy, safety, or any other significant patient benefit.
Intellectual Property Rights, when relevant, will be safeguarded.
Previous research activity and publications will be a major component for the assessment of proposals.
Applications will be reviewed by an independent panel of internationally recognised experts who have provided leadership throughout their long careers in the field of rare diseases.
For the 2024 Award, the Review Committee is composed of:
Dean for Genetics and Genomic Medicine, Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences, The Icahn School of Medicine at Mount Sinai, New York City, NY, USA
Robert J. Desnick is Dean for Genetic and Genomic Medicine and Professor and Chairman Emeritus of the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai.
In 1977, he joined the Mount Sinai faculty as the Arthur J. and Nellie Z. Cohen Professor of Pediatrics and Genetics, and Chief of Medical and Molecular Genetics. From 1993-2011, he was the first Chairman of the Department of Genetics and Genomic Sciences at Mount Sinai. In 2011 he became the Dean for Genetics and Genomic Medicine.
Dr. Desnick’s research interests include lysosomal storage diseases (LSDs) and the inborn errors of heme biosynthesis, the porphyrias, and in particular, their treatment. His
research efforts led to the Federal Drugs Administration (FDA) - and European Medicine Agency (EMA) - approval of enzyme replacement therapy (ERT) for Fabry disease (Fabrazyme) and on-going ERT clinical trials (FDA “Breakthrough” status) for Niemann- Pick B disease, both in partnership with Genzyme. In addition, he was a scientific founder of Amicus Therapeutics (NASDAQ; FOLD), which is developing oral pharmacologic chaperone therapy for Fabry disease (EMA-approved in 2016), Pompe disease, and other disorders. Currently, his laboratory is using gene editing technology to engineer gene therapy in the mouse model of Fabry disease with Sangamo Therapeutics.
Prof. Robert J. Desnick
Prof. Andrew Pearson, M.D., PhD., Retired Cancer Research Professor of Paediatric Oncology, Institute of Cancer Research and the Royal Marsden Hospital NHS Trust, Sutton, UK
Retired Cancer Research UK Professor of Paediatric Oncology, Institute of Cancer Research and the Royal Marsden Hospital NHS Trust, Sutton, UK
Prof Andy Pearson is formerly a Cancer Research UK Professor of Paediatric Oncology, at the Institute of Cancer Research and the Royal Marsden Hospital NHS Trust. In May 2014 he retired due to ill health from The Institute of Cancer Research and Royal Marsden NHS Foundation Trust. Prior to 2005, he had been a Professor of Paediatric Oncology, at the University of Newcastle upon Tyne and Dean of Postgraduate Studies, Faculty of Medical Sciences, at the University of Newcastle upon Tyne. Professor Pearson trained at Newcastle upon Tyne and was Lilly International/Medical Research Council Travelling Fellow at the University of Minnesota, USA.
Professor Andy Pearson expertise is in the fields of drug development and neuroblastoma and has over 45 years’ experience in clinical paediatric oncology. He was the first Chair of the United Kingdom Children Cancer Study Group (UKCCSG) Neuroblastoma Group, Chair of the European Neuroblastoma Group, and was the founding chair of the International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN). He is on the Advisory Board of SIOPEN. He and Professor Sue Cohn of Chicago created and chair the International Neuroblastoma Risk Group Consortium (INRG). He was President of the Advances in Neuroblastoma Research Association from 2012 - 2014 and was on the ANRA Advisory Board for Europe and Russia since 2006. He was Chairman of the UKCCSG from 2003 - 2006. Professor Pearson was the Chief Investigator of the clinical trial ENSG 5 which changed the standard practice for the therapy of high-risk neuroblastoma in Europe. He was the first Chief Investigator of the BEACON Trial; the first randomized European study for refractory/relapsed neuroblastoma. He has published over 400 scientific manuscripts. Professor Pearson led the first paediatric phase I study in the UK. He has been involved in the pre-clinical and early clinical development of many anticancer agents in children. He is a member of the Executive of the Innovative Therapy for Children with Cancer Consortium (ITCC). He is a Chair of ACCELERATE, EMA, and FDA Paediatric Strategy Forum Oversight Committee, Senior Advisor, and member of the Steering Committee of the ACCELERATE to improve drug development for children and adolescents with cancer. He was Chair of the National Cancer Research Institute Children’s Cancer and Leukaemia Clinical Studies Group Novel Agents Subgroup and a member of the New Agents Committee of Cancer Research UK. He led a comprehensive paediatric drug development program, with one of the largest portfolios of early phase, first in child, biomarker rich studies in Europe at The Institute of Cancer Research and Royal Marsden focusing on neuroblastoma. He has published over 400 scientific
Professor Pearson is chair of Solving Kids Cancer Scientific Advisory Board and Patron and Trustee of Neuroblastoma UK and a member of the Programme Committee of
Fight Kids Cancer. He was awarded a Life Time Achievement Award from Advances in Neuroblastoma Research in 2016.
Prof. Andrew Pearson
Prof. Charles Patrick Reynolds, M.D., PhD., Cancer Center Director, Professor of Pediatrics,
Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center, Lubbock, USA, Director of the South Plains Oncology Consortium, and the ALSF/COG Childhood Cancer Repository
Dr. Reynolds grew up in El Paso, TX, received his BA in Biology from The University of Texas at Austin, his MD from UT Southwestern Medical School in Dallas, TX, his PhD (Cell Biology) from UT Austin, and his pediatrics training at the National Naval Medical Center. His postdoctoral fellowship was in cancer immunology at UT Southwestern Medical School, Dallas, TX. He holds the rank of Commander, US Navy (retired). He is currently the Cancer Center Director for the School of Medicine, Texas Tech University Health Sciences Center (http://cancer.ttuhsc.edu), and is Director of the South Plains Oncology Consortium (SPOC: www.SPONC.org) and the ALSF/COG Childhood Cancer Repository (www.CCcells.org).
Dr Reynolds’ research focuses cancer developmental therapeutics and he pioneered the development of the differentiating agent isotretinoin for treating the childhood cancer neuroblastoma. His most recent research focuses on two areas: 1) Use of telomere maintenance mechanisms as cancer biomarkers for neuroblastoma and other cancers and developing agents to specifically target alternate telomere lengthening (ALT) cancers. 2) Assessing GD2 expression on neuroblastoma cells as a mechanism of resistance to chemoimmunotherapy and developing novel non-GD2 anti-neuroblastoma antibodies. Other research interests include mechanisms of resistance to drugs and antibody therapy in childhood and adult cancers, biobanking of human cancers, and development of novel preclinical testing systems for cancer drug development.
Dr. Reynolds is a member of the neuroblastoma steering committee for the Children’s Oncology Group (COG). He was a special government employee with the FDA for 20 years and a founding member of the Pediatric Subcommittee of the Oncologic Drugs Advisory Committee for the FDA. He is a founding member of the Advisory Committee on Childhood Cancer and the Clinical Trials Committee and the Clinical Trials Advisory
Committee for the Cancer Prevention and Research Institute of Texas (CPRIT). He has served on multiple NIH study sections. He is a member of the BPCA Pediatric Oncology Working Group for the National Institute for Child Health and Development. Honors received include the 2004 Eurand Prize, 2008 Advances in Neuroblastoma Research Best Clinical Paper, the most cited paper in Clinical Cancer Research in 2009, The Texas Tech Chancellor’s research award, the Covenant Health Systems David R. Close, MD Endowed Chair in Oncology, and TTUHSC Distinguished University Professor.
Dr. Reynolds has sponsored multiple investigational New Drug (IND) applications with the FDA and receives grant funding from the NIH, DOD, and CPRIT. Dr. Reynolds is an author or co-author of over 250 peer-reviewed scientific papers with > 30,000 citations (H Index = 86) and he is a co-inventor on multiple issued and pending patents. He serves on the editorial boards of Clinical Cancer Research and Molecular Cancer Therapeutics. His avocations include film making and special effects, playing guitar, and writing music. He also enjoys competitive shooting and he was the team physician for the 1992 USA Olympic shooting team in Barcelona.
Prof. Charles Patrick Reynolds
The winning project will be formally announced during an Award Ceremony at SIOP Europe Congress (International Society of Pediatric Oncology Europe) which will be held in Italy from 13th to 17th May 2024.
The 2024 Award will be given to basic, translational, preclinical, and clinical research projects focusing on neuroblastoma are eligible.
The winning project will receive a € 100,000 research grant
The Application will follow a two-step selection process:
1) Preselection: from June 1st 2023 to September 30th 2023
Initial proposals in English must be submitted online in the preselection period described above and should include:
a Letter of Intent (see below)
the Project Summary Page (see below) describing the proposed project in 1200 words (plus one page for figures and/or tables).
The Application Form for the initial proposals must be submitted online at: www.prize.recordati.it
Applicants who submit an initial proposal will receive an email confirming receipt.
The Review Committee, and ad hoc experts, if needed, will evaluate all initial proposals to determine which Applicants will be invited to submit Full Research Project Applications.
Projects eligible for Full Research Project Application will be communicated to the Applicant by November 15th, 2023.
Applicants should be independent junior faculty who are not more than ten years from their terminal degree or eight years from the end of their fellowship and who are not employed full-time with a pharmaceutical company.
The Applicant must be the Principal Investigator of the research project and her/his role in the project must be clearly delineated.
The Applicant’s CV should be included.
Applicants should use the Application Form and comply with instructions.
Projects sponsored by other pharmaceutical companies
Projects already completed.
2) Full Applications: from November 16th, 2023 to February 28th, 2024
Applicants of the selected initials proposals will be invited to submit a Full Research Project Application for competitive review.
Full Research Project Applications instructions must be downloaded from www.prize.recordati.it
The Review Committee will assess and select the winning project based on the quality
of the proposed research.
The Review Committee will follow the “code of conduct” guidance to ensure that reviews are conducted in a fair and equitable manner. The members of the Review Committee are bound by the confidentiality rules generally applicable to such committees.
Applications from the Review Committee members or from faculty of their respective institutions will not be considered.
The Review Committee’s decision is final and there is no appeal mechanism.
2024 Preselection: initials proposal instructions
The Application Form must include a Letter of Intent and the Project Summary Page.
The steps to apply are the following:
Preselection of the initial proposals is based on the Letter of Intent and the Project Summary Page.
Applicants of the selected initial proposals will be invited to submit Full Research Project Applications to compete for the Award by November 15th, 2023.
The selection of the winning project will be based on the evaluation of the Review Committee, and if necessary, ad hoc experts, who will assess the quality of the research as well as the potential impact of the results.
Letter of Intent
The Letter of Intent is an endorsement of the Principal Investigator and the proposed project by an administrative official of the Applicant’s medical school, hospital, or research institute.
Project Summary Page
In 1200 words (plus one page for figures and/or tables) not including reference (Font: Times New Roman 12 or Arial 11, all margins 0.5 inches / 12.7 mm), succinctly describe the proposed project including:
background, unmet needs, and significance of the project;
specific aims, objectives, or hypothesis;
preliminary studies and data relevant to the proposed project;
experimental design: description of methods and analyses to be performed for basic and translational research projects. If a clinical trial is proposed, present the trial design, with primary & secondary endpoints, as well as a statistical plan.
expected results and expected timeframe for completing the project.
Applicants should feel free to add any additional information/supportive data, as needed within the 1200 words limit.